Navigation Links
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
Date:4/29/2009

The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.

The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.

In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.

"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."

About the Report

Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Renal function and heart disease, and more
3. Environmental stress probed in cardiovascular disease, diabetes
4. Study Links Coronary Disease, Colon Cancer
5. People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter
6. To fight disease, animals, like plants, can tolerate parasites
7. Researchers Spot Link Between Heart Disease, Income
8. Children with sickle cell disease, silent strokes show some relief with blood transfusions
9. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
10. U.S. Deaths Down From Heart Disease, Stroke
11. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: